Inventiva (EPA:IVA), (NASDAQ:IVA) is a biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of diseases with significant unmet medical need, particularly in the realms of fibrosis, lysosomal storage disorders, and oncology. Its pipeline is led by lanifibranor, which is in Phase IIb development for the treatment of nonalcoholic steatohepatitis (NASH), a serious liver disease. Inventiva is also advancing a second candidate, odiparcil, aimed at treating patients with mucopolysaccharidosis, a group of lysosomal storage disorders. With each project, Inventiva aims to leverage its expertise in nuclear receptor, transcription factor, and epigenetics to discover and develop novel therapeutics. The company is also listed on the Euronext Paris under the ticker (EPA:IVA), indicating its commitment to expanding its reach and enhancing shareholder value through multiple market presences.